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A B ST R AC T 
 
 
Morphea or localized scleroderma is an uncommon autoimmune and 
inflammatory disease which affects patients of any age. Even if morphea 
lesions present systemic symptoms as myalgias or arthritis, it is distinct from 
systemic sclerosis because it does not associate Raynaud’s phenomena or 
sclerodactyly, which are encountered in systemic scleroderma. The most 
common form of morphea in children is `en coup de sabre`, which can alter 
the local anatomy by deep tissue involvement. In contrast, the most frequent 
form that affects adults is represented by circumscribed morphea. The initial 
lesions present an inflammatory phase that manifests in the form of 
erythematous plaques, sometimes accompanied by edema. In later stages, the 
inflammation decreases and the lesions become sclerotic to atrophic. Therapy 
is most beneficial when initiated in the inflammatory stage. Topical 
application of high potency steroids along with phototherapy demonstrates 
the best results in the active phase of the disease. Localized superficial 
morphea can be treated with the excimer laser (using ultraviolet type B light, 
in range of 308nm) if topical steroid administration shows no significant 
clinical improvement. Phototherapy with ultraviolet light is capable of 
decreasing inflammation and may also have immunomodulatory effects. 
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Introduction  
Morphea or localized scleroderma is an uncommon 
fibromatous disease of the connective tissue in the skin 
and subdermal structures. The disease is characterized 
by the production of excess collagen deposits in the 
skin, causing its thickening [1]. The deposits of collagen 
usually involve the reticular dermis (in the classical 
form of morphea) but can expand into the subdermal 
layer [2]. Superficial morphea (SM) is a particular/ 
uncommon entity characterized by a localized deposition 
of additional collagen in the papillary dermis and upper 
reticular dermis [3], being first described by McNiff in 
1999 [4]. Patients who chose the excimer laser therapy 
generally have followed a 6-8-week treatment with 
topical corticosteroids and often multiple sessions of 
UVA treatment, all these options being used for anti-
inflammatory purposes. Basically, when patients 
receive recommendation for UVB or UVB narrow 
band, the excimer laser treatment represents a viable 
therapeutic alternative for dermatologists. In 
superficial morphea, the literature often describes 
multiple hyperpigmented and slightly indurated patches 
or plaques, distributed especially on the trunk and 
intertriginous areas [5]. Occasionally, purple borders 
may occur (suggesting the acute inflammatory phase), 
as well as minimal atrophy and hypopigmented areas in 
the hyperpigmentation spots [6]. 
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The clinical diagnosis of morphea can be confirmed 
by histopathological examination which highlights the 
excessive bundle deposits of thickened collagen in the 
papillary dermis and reticular dermis. The purpose of the 
therapy is to improve induration and hyperpigmentation, 
to decrease inflammation, and to stop the progression of 
the lesions. 
Discussions 
The term morphea was first used in Ancient Greece to 
describe the form or structure of objects. Nowadays, the 
entity of morphea refers to a chronic autoimmune disorder 
related to unknown conditions, which has a genetic 
predisposition, and which is characterized by sclerotic 
changes in the skin.  Another term for this disorder is 
“localized scleroderma.”  
It may be challenging to distinguish localized 
scleroderma from scleroderma. Scleroderma, better 
known as systemic sclerosis, is a distinct autoimmune 
connective tissue disorder that can involve cutaneous 
sclerosis and systemic manifestations other than those 
observed in morphea.  
Morphea is a fairly rare disease that can develop at 
any age, but most often affects adults [7]. The ratio 
between genders reflects a 3:1 fraction in favor of female 
distribution [7].  The most frequent manifestation of the 
disease in children represents the linear form, while for 
adults the clinical expression is usually the circumscribed 
plaques form. Regarding prevalence related to ethnicity, 
Caucasians are more likely to suffer from the disease than 
African-Americans [8]. The clinical appearance of 
morphea could be as a single localized lesion, or a single 
lesion which can affect half of the forehead (en coup de 
sabre), or an extensive form affecting half of the body [9], 
or in the form of a disseminated disease with multiple 
localizations affecting the entire body [10]. The clinical 
course of the disease may follow two paths. More 
frequently, the disease activity may persist for 3-6 years. 
In fewer cases, the disease activity can become persistent 
and recurring.  
Risk factors for developing the disease have been 
described in various studies. The immune component, 
which has an abnormal response to different triggers, is 
thought to be the key element in the pathogenesis of 
morphea. Different kinds of infectious episodes are 
related to the onset of this inflammatory disorder of the 
skin. As an example, studies performed in Europe have 
revealed a connection between Borrelia infection and 
morphea lesions [10,11]. These studies have noted high 
levels of antibodies against Borrelia burgdorferi in 
patients suffering from morphea. Another finding 
demonstrated the presence of these microorganisms in 
biopsies performed from lesions of morphea. Other 
studies question this outcome and claim that a certain type 
of morphea lesions could be caused by certain species of 
Borrelia found only in Europe and Asia, but not identified 
in the USA [12]. There have been reported cases of 
morphea after administration of biological therapy with 
ustekinumab, a human monoclonal antibody which blocks 
interleukin (IL)-12 and IL-23 via P40, more specifically 
their common protein subunit [13]. Other factors in the 
etiology of morphea include cutaneous radiation, skin 
trauma such as surgery or injections, and insect bites 
[14,15].  
Regarding pathogenesis, morphea is usually described 
as an autoimmune-mediated inflammatory disease. The 
inflammatory infiltrate shown in morpheic lesions is 
composed from T lymphocytes, plasmocytic cells, and 
eosinophils. Laboratory tests performed on morphea 
patients have revealed high levels of autoimmune 
antibodies, especially antinuclear antibodies. The key 
element in the pathogenesis of morphea is the increased 
production of collagen types I and III. This production is 
generated by platelet-derived growth factor, connective 
tissue growth factor, and matrix metalloproteinases [16]. 
All these factors decrease gamma interferon, a suppressor 
of collagen synthesis.  
The morpheic lesions develop insidiously and arise as 
erythematous edematous plaques due to the initial 
inflammatory process. In time, the center of the lesion 
becomes sclerous and the periphery of the lesion 
highlights a violaceus border. Sclerotic lesions are 
characterized by follicular atrophy and hypo/ 
hyperpigmentation, and eventually the lesions become 
atrophic.  
Subtypes of morphea include circumscribed (plaques) 
morphea lesions, linear, deep, and generalized. The 
circumscribed form is most common in adults and it 
presents with indurated round-oval plaques. The linear 
form, which mostly affects children, occurs with 
morpheic form plaques arranged in linear distribution. En 
coup de sabre lesions involve morpheic lesions to the 
cephalic region. It resembles the cut of a sword and 
manifests as a linear atrophic plaque. Although it usually 
affects the forehead, its progression to the scalp may 
induce scarring alopecia. The generalized morphea is 
manifested by the presence of at least 4 plates, on at least 
two anatomical sites. Contrary to the systemic sclerosis, 
generalized morphea does not involve Raynaud’s 
phenomenon, sclerodactyly, and capillary changes 
observed at capillaroscopy [17]. The deep morphea 
subtype refers to the deep dermis and subcutaneous tissue 
involvement.  
Systemic symptoms related to morphea include 
carpal tunnel syndrome and muscular and skeletal 
involvement such as arthritis and myalgias. En coup de 
sabre lesions may produce neurological and ocular 
complications. The coexistence of SM with other skin 
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diseases is uncommon. Saleh and Colab reported the 
case of a patient who presented both psoriasis vulgaris 
and MS [18]. There are reports of association between 
morphea and viral hepatitis C [19].  
Regarding differential diagnosis, several disorders 
have raised, and continue to raise, differential diagnostic 
difficulties. Therefore, numerous controversies occur 
regarding the relationship between superficial morphea 
and Pasini-Pierini atrophoderma. Some authors consider 
both entities to be similar or even identical, especially 
regarding the atrophic phase of morphea [20, 21], whereas 
other authors distinguish between the two diseases. This 
hypothesis is sustained not only by the anomaly of the 
elastic fibers, the sclerosis of collagen bundles, and the 
presence of active inflammation in the regressed lesion of 
superficial morphea, but also by "the Sign of the rock" 
that is characteristic for atrophoderma [22-24]. The most 
important differential diagnosis regarding morphea 
lesions is lichen sclerosus et atrophicus. Lichen sclerosus 
et atrophicus represents a different entity, characterized 
histo-pathologically by epidermal thinning or atrophy, 
follicular hyperkeratosis, vacuolar change of the basal 
layer, dermal edema, and marked loss of elastic fibers 
[25-27]. The diagnosis of morphea is primarily based on 
cutaneous biopsy of the lesions performed for 
histopathological examination. The histopathological 
examination reveals the presence of thick bundles of 
collagen in the dermis. In superficial morphea, the 
modifications of collagen fibers can be observed in the 
papillary dermis and possibly in the superficial reticular 
dermis, while in the classical form of morphea, the 
excessive deposition of collagen bundles are also visible 
in the reticular and deep dermis. The histopathological 
examination must also specify the density of the 
fibroblasts and the density of elastic fibers, which can be 
performed after special colorations with Verhoeff – Van 
Gieson (VVG), Orceine, and Trichrome [27, 28].  The 
biopsy should be performed taking into account the 
resulting ulceration that can be difficult to treat and which 
can even become infected. 
Morphea is an autoimmune inflammatory disorder in 
which the cutaneous atrophy begins to evolve after the 
inflammation phase fades. The treatment is often local 
and includes phototherapy. In more severe cases, systemic 
therapy may be instituted to prevent (at least in part) 
massive involvement of the skin and subcutaneous tissue, 
related to major disfigurement and functional impairment. 
The most responsive forms of morphea to therapeutic 
effects are recent lesions with inflammatory signs. In such 
cases, topical treatment and phototherapy can improve the 
erythema and the regrowth of the hair follicles. In the 
active disease stage, the treatment aim is to limit 
formation of new plaques. Topical treatment options 
include high potency corticosteroids with their well-
studied adverse reactions and microbiome changes [29-
31], topical calcineurin inhibitors, and topical vitamin D 
analogues [32-35]. Tacrolimus, a calcineurin inhibitor, 
has been shown to inhibit development of fibroblasts in 
vitro and in vivo [36-38], leading to a successful 
management in superficial new plaques of morphea.  
Phototherapy has been used as monotherapy or in 
combination with topical medication. Long wavelengths 
such as ultraviolet type A (320-400nm) are beneficial in 
the treatment of sclerotic disorders, due to capability to 
penetrate under the epidermis layer, into the subcutis. 
Ultraviolet light type B such as UVB or narrowband UVB 
(280-315) has the penetrability level reaching the 
papillary dermis. The risk involved in using this type of 
treatment includes sunburn, erythema, and blistering. It 
has been proposed that UV increases the production of 
interferon gamma (which has the ability to decrease the 
synthesis of collagen) and also decreases collagen I and 
III from the morpheic lesions (through decreasing its 
synthesis) [37, 38]. Another effect of UV light in sclerotic 
diseases is related to the action of increasing collagenase 
enzymes [39-41] that induce collagen breakdown.  
Phototherapy represents one of the most common 
treatments in morphea taking into account the clinical 
outcomes. Exposure of the cutaneous lesions to ultraviolet 
light has been proven beneficial over time. Mechanisms 
involving the decrease of collagen production or the 
increase in collagen enzymes have been observed in many 
studies. Presumably, fibroblasts augment the production 
of metalloproteinase extracellular matrix after exposure to 
UVA light [42, 43]. Another important finding suggests 
that exposure to UVA light decreases inflammatory cells 
that sustain the clinical expression of this disorder. 
Several studies show that after UVA radiation, there is a 
decrease in inflammatory cells as lymphocytic T cells, 
mast cells, and Langerhans cells [44]. UVB has shown the 
potential to enhance the receptor for α-melanocyte-
stimulating hormone, causing the release of 
metalloproteinase extracellular matrix [45]. Systemic 
therapy in morphea is usually necessary in patients with 
severe and disfiguring disease forms, or in patients 
diagnosed with generalized acute or progressive morphea. 
The use of methotrexate on such patients is required, but 
relapses may occur at cessation of the medication. It may 
be useful to combine methotrexate with systemic steroids.  
Depth of lesion, lesion localization, and cosmetic 
considerations are important factors contributing to a 
lower quality of life in patients diagnosed with morphea. 
Physical and occupational therapy are required when 
generalized or deep morphea (affecting the subcutaneous 
fat or muscles) occur. Another option for patients who 
suffer from advanced cosmetic lesions (often on the face) 
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is represented by filler therapy. In patients with severe 
contractures, surgery may represent a viable therapeutic 
option [44-46]. 
Conclusions 
Morphea is an autoimmune inflammatory skin 
condition which affects both children and adults. It is 
characterized by an acute phase which involves an 
inflammatory process of the skin, in which the active 
plaques are increasing in size and present an indurated 
erythematous, violaceus border. Over time, the 
inflammation decreases in the center of the lesion and 
atrophy appears. The histopathological appearance of the 
lesions depends on the stage of the disease. The 
inflammatory infiltrate, localized perivascular and into the 
interstitial tissue, consists of T lymphocytes, mast cells, 
eosinophils and plasma cells. When sclerosis occurs, the 
histopathology examination reveals thickened collagen 
bundles into the papillary and reticular dermis up to the 
subcutaneous layer. The course of the disease is mainly 
chronic even though it is often asymptomatic. The most 
important characteristic for treatment is the ability to 
reduce the local inflammatory reaction and to stop the 
progression of the disease. In terms of atrophic lesions, 
treatments are limited, and sclerosis is very difficult to 
treat. Surgery of the lesions is an option as well as 
injections of fillers.   
Our experience with the excimer laser, based on UVB 
308 nm showed an important beneficial therapeutic effect 
mainly on the inflammatory lesions, characterized by 
erythematous plaques or edematous patches.  
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